Biliary Tract Cancers Btcs Pipeline Insight
DelveInsight’s, “Biliary Tract Cancers (BTCs) - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Biliary Tract Cancers (BTCs) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Biliary Tract Cancers (BTCs) Understanding
Biliary Tract Cancers (BTCs): Overview
Biliary Tract Cancers (BTCs) (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.
"Biliary Tract Cancers (BTCs) - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Biliary Tract Cancers (BTCs) pipeline landscape is provided which includes the disease overview and Biliary Tract Cancers (BTCs) treatment guidelines. The assessment part of the report embraces, in depth Biliary Tract Cancers (BTCs) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Biliary Tract Cancers (BTCs) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Tract Cancers (BTCs) R&D. The therapies under development are focused on novel approaches to treat/improve Biliary Tract Cancers (BTCs).
Biliary Tract Cancers (BTCs) Emerging Drugs Chapters
This segment of the Biliary Tract Cancers (BTCs) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Biliary Tract Cancers (BTCs) Emerging Drugs
Pembrolizumab: Merck & Co.
Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. Currently, it is in Phase III stage of clinical trial evaluation to treat Biliary Tract Cancers (BTCs)s.
Disitamab vedotin: RemeGen
Disitamab Vedotin (RC48) is a novel anti-HER2 antibody-drug conjugate (ADC) which is currently across various solid tumor types. It was the first domestically-developed ADC in China approved by the CDE for clinical development in China. ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells. Currently, it is in Phase II stage of clinical trial evaluation to treat Biliary Tract Cancers (BTCs)s.
Further product details are provided in the report……..
Biliary Tract Cancers (BTCs): Therapeutic Assessment
This segment of the report provides insights about the different Biliary Tract Cancers (BTCs) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Biliary Tract Cancers (BTCs)
There are approx. 50+ key companies which are developing the therapies for Biliary Tract Cancers (BTCs). The companies which have their Biliary Tract Cancers (BTCs) drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.
DelveInsight’s report covers around 50+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Biliary Tract Cancers (BTCs) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Biliary Tract Cancers (BTCs): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Biliary Tract Cancers (BTCs) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Biliary Tract Cancers (BTCs) drugs.
Biliary Tract Cancers (BTCs) Report Insights
- Biliary Tract Cancers (BTCs) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Biliary Tract Cancers (BTCs) Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Biliary Tract Cancers (BTCs) drugs?
- How many Biliary Tract Cancers (BTCs) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Biliary Tract Cancers (BTCs)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Biliary Tract Cancers (BTCs) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Biliary Tract Cancers (BTCs) and their status?
- What are the key designations that have been granted to the emerging drugs?